Torna alla classifica

Henry Schein, Inc. (HSIC)

NEUTRAL
HealthcareMedical DistributionUnited States

Fondamentale

57

Prezzo

$89.61

Capitalizzazione

$9.93B

Parte 1 · Quanto vale l'azienda

Panoramica

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Per questa società non c'è ancora una scheda redazionale

Concorrenti diretti

Con chi questa società si contende gli stessi clienti

Per questa società non c'è ancora una scheda redazionale

Per questa società non c'è ancora un elenco di concorrenti.

Stato Patrimoniale e Liquidità

Ricavi

$13.60B

Ultimi 12 mesi (al 27/06/2026)

Utile Netto

$403M

Ultimi 12 mesi (al 27/06/2026)

Free Cash Flow

$573M

Patrimonio Netto Totale

$3.25B

Passività Totali

$6.42B

Rapporto di Liquidità

1.32

Copertura Interessi

4.28

Debito/EBITDA

3.96

Utile per Azione

Ricavi e Utile Netto

Free Cash Flow

Scomposizione Ricavi

Prospetto storico

Margini nel tempo

Il debito nel tempo

Quanto pesa il debito

Griglia della crescita

Crescita — Ricavi

Stima del Fair Value

Correttamente Valutato

Fair Value

$78.56

Prezzo Attuale

$89.61

Margine di Sicurezza

-14.1%

Range Fair Value

$54.32 - $102.80

Metodi di Stima

Analyst Target:$98.19
DCF:$100.01
PE-based:$51.62
Graham Growth:$43.59
EPV:$51.55
Consenso Analisti:Buy (14B / 10H / 1S)
Ultima Sorpresa Utili:+0.67%

Metriche di Valutazione

Rapporto P/E

26.10

ROE

12.3%

Rapporto P/B

3.16

P/FCF

17.53

Margine Lordo

31.3%

ROIC

6.8%

Radar Redditività

Creazione di Valore (Vantaggio Competitivo)

ROIC

6.8%

WACC

7.5%

ROIC − WACC

-0.7 pp

Il ROIC è in linea con il costo del capitale: l'azienda copre a malapena il costo del capitale.

Criteri di Analisi Fondamentale

Superati (17)

  • EPS shows upward trend
  • ROIC 6.8%
  • Gross Margin 31.3%
  • P/FCF 17.53
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.4%
  • Revenue Growth 5Y 5.4%
  • Analyst Consensus 56% Buy
  • Earnings Surprise avg 3.5%
  • Earnings Quality (OCF/NI) 1.74
  • Share Dilution -4.8%

Non superati (10)

  • EPS CAGR 1.29%
  • Price CAGR 4.05%
  • P/B Ratio 3.16
  • Operating Margin 5.0%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 8.40
  • Net Margin Trend 3.0% vs 3.0%
  • Piotroski F-Score 4/9

Non disponibili (1)

  • Dividend Payout NaN%

Piotroski F-Score

4/9

Segnali misti: alcune aree necessitano attenzione

score
criteria

Qualità degli Utili

1.74

Alta qualità: utili supportati da cash

Diluizione Azionaria

-4.8%

Riacquisto azioni. Favorevole agli azionisti

Governance

Team Dirigenziale

NomeRuoloEtà
Mr. Ronald N. SouthSenior VP & CFO63
Mr. Michael Saul EttingerExecutive VP & COO64
Mr. Mark E. MlotekExecutive VP & Chief Strategic Officer69
Mr. Andrea AlbertiniChief Executive Officer of Global Distribution & Technology55
Mr. Frederick M. LoweryCEO & Director54
Ms. Olga TimoshkinaVP of Corporate Finance & Chief Accounting Officer-
Mr. Christopher PendergastSenior VP & CTO62
Mr. Graham StanleyVP of Investor Relations & Strategic Finance Project Officer-
Ms. Kelly Murphy J.D.Senior VP & General Counsel44
Ms. Christine SheehySenior VP & Chief Human Resources Officer57

Rischio Audit

5

Rischio CdA

8

Rischio Compensi

7

Rischio Diritti Azionisti

4

Parte 2 · Il prezzo e il momento d'ingresso

Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.

Ultime Notizie

Ultime notizie per HSIC, da Markets Gazette.

  • 6/11/2026POSITIVE
    This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.

  • 2/24/2026NEUTRAL
    Henry Schein (HSIC) Q4 2025 Earnings Transcript

    Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.

via Markets Gazette